Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
Surrozen has submitted an Investigational New Drug application to the FDA for SZN-8141, a bifunctional antibody that combines FZD4-mediated Wnt agonism with VEGF antagonism, targeting diabetic macular edema. The candidate will be tested in the DUET Phase 1b/2a study, which Surrozen expects to initiate in DME patients by year-end 2026, with initial data anticipated in the second half of 2027. In preclinical rodent models, SZN-8141 showed superior activity versus either Wnt agonist or anti-VEGF monotherapy, reducing neovascularization and delivering greater reductions in vascular leakage.
Key figures
- Drug Name
- SZN-8141
- Phase Of Trial
- Phase 1b/2a
- Mechanism
- FZD4-mediated Wnt agonism plus VEGF antagonism in a single bifunctional antibody
- Indication
- diabetic macular edema (DME)
- Trial name
- DUET
- Study start expected
- by year-end 2026
- Initial data expected
- second half of 2027
- Additional indications
- neovascular age-related macular degeneration (wet AMD)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.